{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:03:38Z","timestamp":1793117018837,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93831-7","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T04:48:29Z","timestamp":1742100509000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Leucine-rich Alpha-2 glycoprotein could be clinically useful in active and postoperative Crohn\u2019s disease"],"prefix":"10.1038","volume":"15","author":[{"given":"Taku","family":"Tashiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Otake-Kasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryotaro","family":"Uema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"key":"93831_CR1","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","volume":"160","author":"D Turner","year":"2021","unstructured":"Turner, D. et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for Treat-to-Target strategies in IBD. Gastroenterology 160, 1570\u20131583. https:\/\/doi.org\/10.1053\/j.gastro.2020.12.031 (2021).","journal-title":"Gastroenterology"},{"key":"93831_CR2","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1159\/000487589","volume":"36","author":"L Laterza","year":"2018","unstructured":"Laterza, L. et al. Multiparametric evaluation predicts different Mid-Term outcomes in Crohn\u2019s disease. Dig. Dis. 36, 184\u2013193. https:\/\/doi.org\/10.1159\/000487589 (2018).","journal-title":"Dig. Dis."},{"key":"93831_CR3","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1136\/gutjnl-2011-301397","volume":"61","author":"CN Bernstein","year":"2012","unstructured":"Bernstein, C. N., Loftus, E. V. Jr., Ng, S. C., Lakatos, P. L. & Moum, B. Hospitalisations and surgery in Crohn\u2019s disease. Gut 61, 622\u2013629. https:\/\/doi.org\/10.1136\/gutjnl-2011-301397 (2012).","journal-title":"Gut"},{"key":"93831_CR4","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.gastro.2020.03.039","volume":"159","author":"RC Ungaro","year":"2020","unstructured":"Ungaro, R. C. et al. Deep remission at 1 year prevents progression of early Crohn\u2019s disease. Gastroenterology 159, 139\u2013147. https:\/\/doi.org\/10.1053\/j.gastro.2020.03.039 (2020).","journal-title":"Gastroenterology"},{"key":"93831_CR5","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1136\/gutjnl-2012-302830","volume":"61","author":"MF Neurath","year":"2012","unstructured":"Neurath, M. F. & Travis, S. P. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut 61, 1619\u20131635. https:\/\/doi.org\/10.1136\/gutjnl-2012-302830 (2012).","journal-title":"Gut"},{"key":"93831_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1136\/ard.2009.118919","volume":"69","author":"S Serada","year":"2010","unstructured":"Serada, S. et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann. Rheum. Dis. 69, 770\u2013774. https:\/\/doi.org\/10.1136\/ard.2009.118919 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"93831_CR7","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1172\/jci18921","volume":"111","author":"MB Pepys","year":"2003","unstructured":"Pepys, M. B. & Hirschfield, G. M. C-reactive protein: a critical update. J. Clin. Invest. 111, 1805\u20131812. https:\/\/doi.org\/10.1172\/jci18921 (2003).","journal-title":"J. Clin. Invest."},{"key":"93831_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/01.mib.0000173271.18319.53","volume":"11","author":"CA Solem","year":"2005","unstructured":"Solem, C. A. et al. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm. Bowel Dis. 11, 707\u2013712. https:\/\/doi.org\/10.1097\/01.mib.0000173271.18319.53 (2005).","journal-title":"Inflamm. Bowel Dis."},{"key":"93831_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/ecco-jcc\/jjw132","volume":"11","author":"S Shinzaki","year":"2017","unstructured":"Shinzaki, S. et al. Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. J. Crohns Colitis. 11, 84\u201391. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw132 (2017).","journal-title":"J. Crohns Colitis"},{"key":"93831_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac076","author":"T Kawamura","year":"2022","unstructured":"Kawamura, T. et al. Accuracy of serum Leucine-Rich Alpha-2 glycoprotein in evaluating endoscopic disease activity in Crohn\u2019s disease. Inflamm. Bowel Dis. https:\/\/doi.org\/10.1093\/ibd\/izac076 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"93831_CR11","doi-asserted-by":"publisher","unstructured":"Omori, T. et al. Serum Leucine-Rich Alpha-2 Glycoprotein in Quiescent Crohn\u2019s Disease as a Potential Surrogate Marker for Small-Bowel Ulceration detected by Capsule Endoscopy. J. Clin. Med. 11 https:\/\/doi.org\/10.3390\/jcm11092494 (2022).","DOI":"10.3390\/jcm11092494"},{"key":"93831_CR12","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","volume":"56","author":"S Shinzaki","year":"2021","unstructured":"Shinzaki, S. et al. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J. Gastroenterol. 56, 560\u2013569. https:\/\/doi.org\/10.1007\/s00535-021-01793-0 (2021).","journal-title":"J. Gastroenterol."},{"key":"93831_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15907","author":"I Abe","year":"2022","unstructured":"Abe, I. et al. Serum leucine-rich alpha-2 glycoprotein as a predictive factor of endoscopic remission in Crohn\u2019s disease. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.15907 (2022).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"93831_CR14","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s10620-018-4942-6","volume":"63","author":"J Kusaka","year":"2018","unstructured":"Kusaka, J. et al. Residual lesions on capsule endoscopy is associated with postoperative clinical recurrence in patients with Crohn\u2019s disease. Dig. Dis. Sci. 63, 768\u2013774. https:\/\/doi.org\/10.1007\/s10620-018-4942-6 (2018).","journal-title":"Dig. Dis. Sci."},{"key":"93831_CR15","doi-asserted-by":"publisher","first-page":"88","DOI":"10.4253\/wjge.v6.i3.88","volume":"6","author":"T Kono","year":"2014","unstructured":"Kono, T. et al. Prospective postsurgical capsule endoscopy in patients with Crohn\u2019s disease. World J. Gastrointest. Endosc. 6, 88\u201398. https:\/\/doi.org\/10.4253\/wjge.v6.i3.88 (2014).","journal-title":"World J. Gastrointest. Endosc"},{"key":"93831_CR16","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1002\/ibd.22977","volume":"19","author":"P De Cruz","year":"2013","unstructured":"De Cruz, P., Kamm, M. A., Prideaux, L., Allen, P. B. & Moore, G. Mucosal healing in Crohn\u2019s disease: a systematic review. Inflamm. Bowel Dis. 19, 429\u2013444. https:\/\/doi.org\/10.1002\/ibd.22977 (2013).","journal-title":"Inflamm. Bowel Dis."},{"key":"93831_CR17","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1111\/j.1365-2036.2012.05002.x","volume":"35","author":"A Buisson","year":"2012","unstructured":"Buisson, A., Chevaux, J. B., Allen, P. B. & Bommelaer, G. Peyrin-Biroulet, L. Review Article: the natural history of postoperative Crohn\u2019s disease recurrence. Aliment. Pharmacol. Ther. 35, 625\u2013633. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05002.x (2012).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"93831_CR18","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3748\/wjg.v20.i1.78","volume":"20","author":"T Yamamoto","year":"2014","unstructured":"Yamamoto, T. & Watanabe, T. Surgery for luminal Crohn\u2019s disease. World J. Gastroenterol. 20, 78\u201390. https:\/\/doi.org\/10.3748\/wjg.v20.i1.78 (2014).","journal-title":"World J. Gastroenterol."},{"key":"93831_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1002\/ibd.22936","volume":"18","author":"S Serada","year":"2012","unstructured":"Serada, S. et al. Serum leucine-rich alpha-2 glycoprotein is a disease activity biomarker in ulcerative colitis. Inflamm. Bowel Dis. 18, 2169\u20132179. https:\/\/doi.org\/10.1002\/ibd.22936 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"93831_CR20","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1093\/ibd\/izx082","volume":"24","author":"B Feagan","year":"2018","unstructured":"Feagan, B. et al. Performance of Crohn\u2019s disease clinical trial endpoints based upon different cutoffs for patient reported outcomes or endoscopic activity: analysis of EXTEND data. Inflamm. Bowel Dis. 24, 932\u2013942. https:\/\/doi.org\/10.1093\/ibd\/izx082 (2018).","journal-title":"Inflamm. Bowel Dis."},{"key":"93831_CR21","doi-asserted-by":"publisher","unstructured":"Khanna, R. et al. Endoscopic scoring indices for evaluation of disease activity in Crohn\u2019s disease. Cochrane Database Syst Rev Cd010642 (2016). (2016). https:\/\/doi.org\/10.1002\/14651858.CD010642.pub2","DOI":"10.1002\/14651858.CD010642.pub2"},{"key":"93831_CR22","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/0016-5085(90)90613-6","volume":"99","author":"P Rutgeerts","year":"1990","unstructured":"Rutgeerts, P. et al. Predictability of the postoperative course of Crohn\u2019s disease. Gastroenterology 99, 956\u2013963. https:\/\/doi.org\/10.1016\/0016-5085(90)90613-6 (1990).","journal-title":"Gastroenterology"},{"key":"93831_CR23","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jss.2020.03.018","volume":"252","author":"Z Jin","year":"2020","unstructured":"Jin, Z. et al. The prognostic impact of Leucine-Rich \u03b1-2-Glycoprotein-1 in cholangiocarcinoma and its association with the IL-6\/TGF-\u03b21 axis. J. Surg. Res. 252, 147\u2013155. https:\/\/doi.org\/10.1016\/j.jss.2020.03.018 (2020).","journal-title":"J. Surg. Res."},{"key":"93831_CR24","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/mpa.0000000000000205","volume":"44","author":"K Furukawa","year":"2015","unstructured":"Furukawa, K. et al. Clinicopathological significance of Leucine-Rich \u03b12-Glycoprotein-1 in Sera of patients with pancreatic cancer. Pancreas 44, 93\u201398. https:\/\/doi.org\/10.1097\/mpa.0000000000000205 (2015).","journal-title":"Pancreas"},{"key":"93831_CR25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44, 837\u2013845 (1988).","journal-title":"Biometrics"},{"key":"93831_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1136\/gut.2005.082909","volume":"55","author":"J Satsangi","year":"2006","unstructured":"Satsangi, J., Silverberg, M. S., Vermeire, S. & Colombel, J. F. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55, 749\u2013753. https:\/\/doi.org\/10.1136\/gut.2005.082909 (2006).","journal-title":"Gut"},{"key":"93831_CR27","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/ecco-jcc\/jjz069","volume":"13","author":"A Cremer","year":"2019","unstructured":"Cremer, A. et al. Variability of faecal calprotectin in inflammatory bowel disease patients: an observational Case-control study. J. Crohns Colitis. 13, 1372\u20131379. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz069 (2019).","journal-title":"J. Crohns Colitis"},{"key":"93831_CR28","doi-asserted-by":"publisher","first-page":"11086","DOI":"10.1038\/s41598-021-90441-x","volume":"11","author":"E Yasutomi","year":"2021","unstructured":"Yasutomi, E. et al. Leucine-rich alpha-2 glycoprotein as a marker of mucosal healing in inflammatory bowel disease. Sci. Rep. 11, 11086. https:\/\/doi.org\/10.1038\/s41598-021-90441-x (2021).","journal-title":"Sci. Rep."},{"key":"93831_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.06.036","author":"A Kawamoto","year":"2021","unstructured":"Kawamoto, A. et al. Serum leucine-rich alpha-2 glycoprotein; a novel biomarker for small bowel mucosal activity in Crohn\u2019s disease. Clin. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1016\/j.cgh.2021.06.036 (2021).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"93831_CR30","doi-asserted-by":"publisher","unstructured":"Yoshimura, T. et al. Evaluation of Serum Leucine-Rich Alpha-2 Glycoprotein as a New Inflammatory Biomarker of Inflammatory Bowel Disease. Mediators Inflamm 8825374 (2021). (2021). https:\/\/doi.org\/10.1155\/2021\/8825374","DOI":"10.1155\/2021\/8825374"},{"key":"93831_CR31","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/s0140-6736(14)61908-5","volume":"385","author":"P De Cruz","year":"2015","unstructured":"De Cruz, P. et al. Crohn\u2019s disease management after intestinal resection: a randomised trial. Lancet 385, 1406\u20131417. https:\/\/doi.org\/10.1016\/s0140-6736(14)61908-5 (2015).","journal-title":"Lancet"},{"key":"93831_CR32","doi-asserted-by":"publisher","first-page":"175628481878557","DOI":"10.1177\/1756284818785571","volume":"11","author":"YS Tham","year":"2018","unstructured":"Tham, Y. S. et al. Fecal calprotectin for detection of postoperative endoscopic recurrence in Crohn\u2019s disease: systematic review and meta-analysis. Th. Adv. Gastroenterol. 11, 1756284818785571. https:\/\/doi.org\/10.1177\/1756284818785571 (2018).","journal-title":"Th. Adv. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93831-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93831-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T04:48:31Z","timestamp":1742100511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93831-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93831"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93831-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"27 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S. Shinzaki received contract research funds from Sekisui Medical. All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9031"}}